Table 4.
Studies on anticoagulation resumption after ICH
| First author (year) |
Design | ICH type | N of pts | Indications | Timing of resumption | Anticoagulants | Comparator | Risk of TE | Risk of recurrent ICH |
|---|---|---|---|---|---|---|---|---|---|
|
Majeed [83] (2010) |
Retrospective | Anticoagulation-related | 234 | AF, MV, VTE | Median 5.6 weeks | Warfarin | Without AC | Not mentioned | 8 vs. 10 (HR 5.6, 95%CI 1.8–17.2) |
|
Yung [84] (2012) |
Retrospective | Anticoagulation-related | 284 | AF, MV, VTE | Within a month | Warfarin | Without AC | Not mentioned | 15.4% vs. 15.0% (P = 0.94) |
|
Kuramatsu [85] (2015) |
Retrospective | Anticoagulation-related | 719 | AF, MV, VTE | Median 31 days | OAC | Without AC | 5.2% vs. 15.0% (P < 0.001) | 8.1% vs. 6.6% (P = 0.48) |
|
Witt [86] (2015) |
Retrospective | Anticoagulation-related | 160 | AF, MI, MV, IS, VTE | Median 14 days | Warfarin | Without AC | 3.7% vs. 12.3% (P = 0.092) | 7.6% vs.3.7% (P = 0.497) |
|
Ottosen [82] (2016) |
Retrospective | Spontaneous | 2978 | AF, IS, MI, MV, PAD, VTE | Not mentioned | OAC | Without AC | Lower (HR 0.58, 95%CI 0.35–0.97) | Not increased (HR 0.90, 95%CI 0.44–1.82) |
N of pts number of patients; AF atrial fibrillation; MV mechanical valves; MI myocardial infarction; IS ischemic stroke; PAD peripheral vascular disease; OAC oral anticoagulants; AC anticoagulants; TE thrombotic events; HR hazard ratio